The present study describes a case of the extremely rare histological picture of a lobular carcinoma of the male breast. The 85-year-old patient presented with a tumour in a very advanced stage. The results of genetic studies excluded Klinefelter's syndrome, but a new gene mutation affecting the BRCA1 gene (breast cancer gene 1) was found in the patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/ejso.1999.0891 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Invasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due to advanced stage at diagnosis, late recurrence, and development of resistance to endocrine therapy - a cornerstone of ILC treatment. To elucidate the mechanisms underlying endocrine resistance in ILC, ILC cell lines (MDA-MB-134-VI, SUM44PE) were generated to be resistant to tamoxifen, a selective estrogen receptor modulator.
View Article and Find Full Text PDFRisk Factors for Positive Resection Margins Following Breast-Conserving Surgery.
Cureus
December 2024
Department of Breast, Plastic and Reconstructive Surgery, Royal Hallamshire Hospital, Sheffield, GBR.
Background The incidence of margin re-excision following breast conserving surgery (BCS) is a quality measure in the National Health Service. The threshold is less than 20% of all BCS procedures. Despite three decades of studies and a wealth of literature identifying multiple factors associated with increased risk for margin involvement, an accepted threshold rate affecting one in five procedures remains high.
View Article and Find Full Text PDFBackground: Evaluation of the prognostic performance and clinical utility of the MammaPrint 70-gene signature in early-stage invasive lobular carcinoma (ILC) for whom such analyses in a randomized trial is awaited.
Patients And Methods: Exploratory subgroup analysis of MINDACT trial patients with centrally assessed histology (n = 5929) with invasive breast cancer of no-special-type (NST), or pure ILC. In the trial patients were categorized based on the 70-gene signature for genomic risk and modified Adjuvant!Online for clinical risk.
A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes-Bozyaka Experience.
Cancers (Basel)
January 2025
Bozyaka Education and Research Hospital, University of Health Sciences Turkey, 35170 Izmir, Turkey.
To evaluate the neoadjuvant chemotherapy (NACTx) process in breast cancer (BC), its significant treatment-related adverse events (trAEs), tumor clinical response rates, and surgical and pathological outcomes, and to analyze factors influencing cavity shaving and axillary lymph node dissection (ALND) following sentinel lymph node biopsy (SLNB). A comprehensive retrospective study was conducted at a single center on patients who received NACTx for BC between 2015 and 2021. Medical records of 242 patients were reviewed.
View Article and Find Full Text PDFEnhancers of cancer stem cells and epithelial-mesenchymal transition: Lin28, MUC1, and lipocalin-2 as a new prognostic axis in classical invasive lobular carcinoma of the breast.
Pol J Pathol
January 2025
Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Breast carcinoma is one of the most common causes of cancer-related mortality among women worldwide. The primary objective of the present study was to eva-luate the expression of the epithelial-mesenchymal transition (EMT)-related markers Lin28, MUC1, and lipocalin-2 in invasive lobular carcinoma (ILC) and to investigate their correlation with clinicopathological characteristics and patient survival. This prospective cohort study included 120 classic ILC cases investigated for immunohistochemical expressions of Lin28, MUC1, and lipocalin-2 and followed them for five years or until death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!